FDA OKs BrainLab radiosurgery planning software

TriMed Staff | | Health Imaging | Oncology Imaging
BrainLab has received 510(k) clearance from the FDA for its HybridArc radiosurgery planning software.

HybridArc expands upon the Dynamic Arc stereotactic treatment technique to offer high dose conformity to the target. The software package uses an adaptive dose calculation matrix that takes into account the different parameters affecting dose distribution to provide precision when opting for stereotactic radiosurgery.

According to Munich-based BrainLab, HybridArc can be deployed in hospitals that either have Linac treatment technology or those that want to gain the capability of radiosurgery without a hardware upgrade. Treatments can be delivered on most Linac-based radiosurgery systems.

TriMed Staff

Related Content

High-intensity focused ultrasound could allow prostate cancer patients to avoid surgery
MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.